Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Gyre Therapeutics Q3 2026 Results: Net Loss of $2.48M

Gyre Therapeutics reported a net loss of $2.48 million for the third quarter of 2026, compared to a net income of $1.93 million in the same period of 2025. Total revenues remained relatively flat at $32.93 million, while operating expenses increased significantly, particularly in research and development and general and administrative costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue32.932.7
Profit before tax-1.72.5
Net income-2.51.9
EPS (diluted, $ a share)$-0.04$0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+0.7%
Operating margin-4.6%
Source

10-Q filed with the SEC, NASDAQ: GYRE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Gyre Therapeutics, Inc.: key numbers

Share price
$4.56Close, Nov 17
Market cap
$526M
Shares outstanding
115.32MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Gyre Therapeutics, Inc.

All →
4:33 PM ET 8-K
Financial Results

Gyre Therapeutics Financial Results

Gyre Therapeutics reported Q3 2026 revenue of $32.9 million and affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million. The company is preparing for a potential China NMPA decision on its liver fibrosis candidate F351 by early 2027 and is advancing several protein degrader programs into clinical trials.

Term
Q3 2026

“I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”

Dr. Ying Luo, President and Chief Executive Officer
4:02 PM ET 8-K
Executive Compensation

Gyre Therapeutics Executive Compensation

Gyre Therapeutics entered into new employment agreements with CEO Ying Luo, Ph.D., and CFO Thomas Eastling to continue their service. The agreements establish annual base salaries of $500,000 and $339,066 respectively, along with target bonuses and severance provisions including salary continuation and accelerated equity vesting upon certain termination events.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.